­­Uri Ben-David

Department of Human Molecular Genetics & Biochemistry, Tel Aviv University

+972-54-6004444 | ubendavid@tauex.tau.ac.il

ORCID ID: 0000-0001-7098-2378

## ACADEMIC POSITIONS

06/2022 to date **Associate Professor**, Department of Human Molecular Genetics & Biochemistry, Faculty of Medicine, Tel-Aviv University.

10/2019-06/2022 **Senior Lecturer (Assistant Professor)**, Department of Human Molecular Genetics & Biochemistry, Faculty of Medicine, Tel-Aviv University.

2014-2019 **Postdoctoral Fellow at the** **Broad Institute of Harvard and MIT**, Cambridge, MA, under the supervision of Prof. Todd R. Golub, Director of Cancer Program.

## EDUCATION

2010-2014  **Ph.D. studies at the Hebrew University of Jerusalem**, Israel, under the supervision of Prof. Nissim Benvenisty, Stem Cell Unit, Dept. of Genetics, Life Sciences Institute. PhD thesis title: “Genomic instability and tumorigenicity of human pluripotent stem cells”.

2009-2010 **M.Sc. studies, Dept. of Genetics, Life Sciences Institute, Hebrew University.**

 Average of M.Sc. studies: **98.4/100**. Direct Ph.D. program entrance exam: **99/100**.

2006-2009 **B.Sc. studies, *summa cum laude,* Life sciences and Cognitive sciences, Hebrew University**. Studies within the excellence program of the Exact Sciences Faculty, “Amirim Teva”. Average of B.Sc. studies: **98/100**.

**TEACHING AND MENTORING EXPERIENCE**

2021 to date Teaching the basic “Introduction to Molecular Biology” course for 1st year medical school students (~200 students)
Accredited by the TAU BLEND Program for Innovation in Teaching & Learning

2020 to date Teaching a graduate level course on “Scientific Writing”

2019 to date Mentoring 3 Staff Scientists, 2 postdocs, 2 PhD students, 3 MD/PhD students, three MSc student, two MD thesis students, and 6 undergraduate students

2016-2018 Coaching in the Cancer Program “Bootcamp” Training

2016-2019 Training and mentoring a full-time Research Associate

2012-2019 Training and mentoring undergraduate students

2012-2014 Teaching assistant at the Hebrew University Life Sciences Institute:
Human Genetics course for 3rd year biology students

2010-2012 Teaching assistant at the Hebrew University Life Sciences Institute:
General Genetics course for 1st year biology students

**PROFESSIONAL TRAININGS**

2023 8400 iTranslate Program for translational research in HealthTech

2023 Tel Aviv University ‘Time Management’ workshop

2021 Azrieli Foundation ‘Storytelling’ Workshop

2020 HFP ‘Grant Writing’ workshop

2020 Tel Aviv University ‘Effective Interviewing’ workshop

2020 Tel Aviv University ‘Team Leadership’ workshop

2019 EMBO ‘Lab Leadership’ Course

## OTHER EXPERIENCE

2011-2014 Translating Latino American literature from Spanish to Hebrew:

Jorge Luis Borges’ *De que nada se sabe*, Carmel Publishing House (2012)

Reinaldo Arenas’ *Celestino antes del alba*, Carmel Publishing House (2014)

2011-2014 Volunteering with high school students (through “Hoshen” organization)

2007-2014 Volunteering with Holocaust survivors (through “Amcha” organization)

2001-2006 Military service as an intelligence officer in a special intelligence unit, **with honors**

## LANGUAGES

Hebrew Native speaker

English Very high level

Spanish Medium level

**INDEPENDENT GRANTS & RESEARCH FUNDS**

Ongoing Active Grants

2023-2024 **The Faculty of Medicine Research Foundation Seed Grant** ($15K total)

2023 **The Israel Cancer Association Research Grant** ($15K total)

2023 **EMBO Young Investigators Small Grant** ($10K total)

2021-2026 **The European Research Council (ERC) Starting Grant** ($1.85M total)

2021-2026 **Israel Science Foundation Project Grant** ($420K total)

2021-2025 **Israel Precision Medicine Partnership (IPMP) Research Grant** (co-PI with Prof. Ittai Ben-Porath and Dr. Amir Sonnenblick; $680K total)

2021-2024 **Israel Science Foundation New Faculty Equipment Grant** ($240K total)

2021-2023 **NovoCure Tumor Treating Fields Research Grant** ($220K total)

2020-2024 **The United States – Israel Binational Science Foundation Research Grant**
(co-PI with Prof. Angelika Amon from MIT; $224K total)

2020-2023 **The Israel Cancer Research Fund ‘Gesher’ Award** ($176K total)

2020-2023 **The Department of Defense (DoD) Peer Reviewed Cancer Research Program (PRCRP) Career Development Award** ($450K total)

2019-2022 **The Azrieli Foundation Faculty Fellowship** ($210K total)

Previous Funding

2021-2022 **The Forbeck Foundation Accelerator Grant** ($30K total)

2021-2022 **The TAU/CBRC-LaTrobe/ONJ Collaboration Grant** (co-PI with Prof. Delphine Merino; $30K total)

2021-2022 **The Clinical-Bioinformatics Collaboration Grant** of the Edmond J. Safra Center for Bioinformatics and the School of Medicine at TAU (co-PI with Prof. Benny Dekel; $20K total)

2021-2022 **The Faculty of Medicine Research Foundation Seed Grant** ($11K total)

2021 **The Schtacher Award for Biomedical Research** ($8K total)

2021 **The WGFRF COVID-19 Recovery Grant** ($15K total)

20202021- **The Israel Cancer Association Research Grant** ($23K total)

2020 **The Cancer Biology Research Center Research Grant** ($20K total)

2019-2020 **The Eimert Research Fund on Solid Tumors** ($50K total)

2019-2022 **The National Cancer Institute (NCI) Career Transition Award (K22)**
($450K total, relinquished)

2019-2024 **Cancer Prevention and Research Institute of Texas** Recruitment of First-Time Tenure-Track Faculty Members ($2M total, relinquished)

2016-2017 The Broad Institute **Broadnext10** research grant ($75K total)

**ACADEMIC AWARDS & SCHOLARSHIPS**

International

2023 **Dr. Joseph Steiner Cancer Research Award 2023** – Finalist (one of six)

2022-2026 **EMBO Young Investigator** Member

2021 **Cells 2021 Young Investigator Award**

2020 The American Association for Cancer Research (AACR) ‘**Next Generation Star**’

 Award

2018 **Pacific Symposium on Biocomputing Research Parasite Award**
for outstanding secondary analysis of data

2016 **AACR-Susan G. Komen Scholar-in-Training Award** for participation at the American Association for Cancer Research annual meeting (New Orleans, USA)

2015 **American Society of Cell Biology** **Kaluza Prize** for outstanding Ph.D. dissertation

2016-2020 **Forbeck Research Foundation Scholar Award** in the field of Aneuploidy and Chromosomal Instability

2015 Selected participant at the 65th **Lindau Nobel Laureate Meeting** (Lindau, Germany)

2015-2018 **Human Frontier Science Program Postdoc Fellowship**

2014-2015 **EMBO Long Term Postdoc Fellowship**

2013 **The Dan David Scholarship Award**, Future Time Dimension, Preventive Medicine

2013 **Best Poster Award**, Israel Stem Cell Society (ISCS) 5th international meeting

2013 **Travel Award Grant** for oral presentation, International Society for Stem Cell Research (ISSCR) 11th annual conference (Boston, USA)

2012 Participant at the **Merck Serono Innovation Cup** 2012

2012 **Travel Award Grant** for oral presentation, International Society for Stem Cell Research (ISSCR) 10th annual conference (Yokohama, Japan)

2011 **Travel Award Grant** for oral presentation, International Society for Stem Cell Research (ISSCR) 9th annual conference (Toronto, Canada)

2010 **Travel Award Grant** for poster presentation, International Society for Stem Cell Research 8th annual conference (San Francisco, USA)

National

2022 **The Wolf Foundation’s Krill Prize** for Excellence in Scientific Research

2014 **Rothschild Postdoc Fellowship**

2012-2014 **Clore Foundation Scholarship** for outstanding Ph.D. students

2011 **Aharon Katzir Student Travel Fellowship**

Institutional

2023 The **Kadar Award** for Outstanding Research

2023 The **Rector’s Award** for **Innovation and Creativity in Teaching**

2023 The **Stolz Award** for Junior Faculty in Medicine and Health Professions

2022 Dean’s Award for **Excellence in Teaching**

2021 **Best Publication Award** for 2021, Faculty of Medicine, Tel Aviv University

2021 **The Schtacher Award for Biomedical Research** for an excellent researcher at the Department of Human Molecular Genetics & Biochemistry

2018, 2019 **Best Poster Award**, The Annual Cancer Genetics Symposium of Dana-Farber and Harvard Cancer Center (Boston, USA)

2015 **The Hans Weiner Prize** for outstanding Ph.D. dissertation, Hebrew University

2014 **The Dimitris N. Chorafas Foundation Award** for outstanding Ph.D. dissertation

2013 **The Kaye Innovation Award**, 1st prize for students

2013 **Menashe Markus Prize** for an outstanding Ph.D. student at the Dept. of Genetics

2010-2014 **Dean’s List of Outstanding Teachers** for the years 2011, 2012, 2013 and 2014

2010-2013 **SMART Prize** for the best article of the month, Life Sciences Institute.

 Awarded five times: Oct 2010, Aug 2011, Feb 2012, Feb 2013 and Aug 2013

2012 **Best Poster Award**, Faculty of Natural Sciences posters contest

2012 **Travel Grant** from the Research Students Authority of the Hebrew University

2011 **SMART Prize** for best article of the year (2010), Life Sciences Institute

2010 **Pollack Prize** for excellent M.Sc. students

2009 **Excellence Scholarship** for M.Sc. students (from Hebrew University)

2008 **Rector’s Prize**, second year of B.Sc. studies

2007-2009 **Dean’s Prize**, first, second and third year of B.Sc. studies

2007-2009 **Excellence Scholarship** for B.Sc. students (“Amirim Teva” program)

**REVIEWING ACTIVITY & EDITORIAL BOARDS**

2023 Associate Editor, PLOS Genetics

2013 to date Ad hoc reviewer of >60 manuscripts for *Nature*, *Science*, *Nature Genetics*, *Nature Cancer*, *Nature Biotechnology*, *Nature Cell Biology*, *Cancer Discovery*, *Cancer Research*, *Nature Reviews Cancer*, *Nature Reviews Drug Discovery*, *Nature Reviews Molecular Cell Biology*, *Nature Reviews Clinical Oncology*, *Cell Systems*, *Science Advances*, *Stem Cell Reports*, *Nature Communications*, *PLoS Computational Biology*, *The EMBO Journal*, *Molecular Systems Biology*, *Nucleic Acids Research*, *npj Precision Oncology*, *iScience*, *Molecular Cancer Therapeutics*, *eLife*, *Chromosome Research*, *Review Commons*, *Stem Cells*, *Stem Cells Translational Medicine*, *PLoS One*, *Communications Biology*, *Seminars in Cell and Developmental Biology*, *Molecular and Cellular Therapies*

2014 to date Ad hoc reviewer of >20 grant applications for the European Research Council (ERC) Starting Grant, Israel Science Foundation (ISF), Israel Cancer Association (ICA), Swiss Cancer Research Foundation, Austrian Science Fund (FWF), Dutch Cancer Society (KWF), Worldwide Cancer Research (WCR), Cancer Research Trust New Zealand, Azrieli Postdoctoral Fellowship Program, Czech Science Foundation, Willy Gepts Research Foundation, International Society for Stem Cell Research (ISSCR), ETH Zurich Latsis Prize, Boehringer Ingelheim Fonds PhD Fellowship

2013-2016 Advisory Board member of *Molecular and Cellular Therapies*

2011-2019 Indirect ad hoc reviewer (through PI) of >20 manuscripts for *Nature*, *Cell*, *Nature Genetics*, *Nature Biotechnology*, *Cell Stem Cell*, *Stem Cell Reports*, *Stem Cells*, *Nature Communications*, *EMBO Molecular Medicine*

**COMMITTEES & ORGANIZATIONAL DUTIES**

National & International

2022 Israel Innovation Authority panel of experts for ERC Starting Grants interview preparation

2021-date BSF Scientific Advisory Panel (regular grants program)

2021 Technion Human Health Initiative (THHI) scientific advisory committee

2020-date Member of Ph.D thesis committees at DKFZ and at Technion (x2)

2019 to date International member of Ph.D. thesis juries:
Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel (VUB), Brussels, Belgium (x2)
Institute of Biomedical sciences, University of Porto, Porto, Portugal

 University of Groningen Medical Center, Groningen, Netherlands

Institutional

2023 Head, TAU-MED Program, TAU

2023 Co-Chair, Safra-Soroka Clinical Bioinformatics Grant Committee

2023-date Member, International Affairs Task Force, Faculty of Medicine, TAU

2023 Member, Committee for Scholarships on the Basis of Social Contribution to the Faculty and to Society

2022-date Academic Head, Genomic Analysis Lab and Single Cell Analysis Core, TAU

2022-date Member, M.D./Ph.D. Committee, Faculty of Medicine, TAU

2022-date Interviewing and evaluating PhD candidates for the Medicine Faculty

2021 Member, Safra Bioinformatics Retreat Program Committee

2020-date Member: Ph.D thesis committees (x4); M.Sc. thesis committees (x6); and M.D. thesis committees (x3)

2020 to date Member, Instrumentation and Service Center Committee,

 Faculty of Medicine, TAU

2020 to date Organizing the weekly Departmental Seminar Series, Department of Human

 Molecular Genetics & Biochemistry, Faculty of Medicine, TAU

2019 to date Reviewing multiple (>10) Faculty grant applications and thesis proposals

**ORAL PRESENTATIONS**

International

2024 FEBS/EMBO Lecture Course on Molecular Mechanisms in Signal Transduction and Cancer, Spetse, Greece (**invited speaker**)

2024 The FASEB Meeting on Consequences of Aneuploidy,
Boston, USA (**invited speaker**)

2023 Fondation des Treilles Meeting on DNA Damage in Mitosis,

 Provence, France (**invited speaker**)

2023 The International PhD Student Cancer Conference (IPSCC),
Cambridge, UK (**invited keynote speaker**)

2023 The Mark Foundation Meeting on Chromosomal Instability,
London, UK (**invited speaker**)

2023 Gordon Research Conference on Molecular Mechanisms of Evolution,
Boston, USA (**invited speaker**; declined due to a time conflict)

2023 The 14th European Cytogenomics Conference,

 Montpellier, France (**invited speaker**)

2023 The Broad-ISF 10th Annual Meeting, Jerusalem, Israel (**invited speaker**)

2023 The European Institute of Oncology (IEO), Milan, Italy (**invited speaker**)

2023 The EMBO Young Investigators Annual Meeting, Milan, Italy (**invited speaker**)

2023 The EMBO/CBRC Joint Symposium, Tel Aviv, Israel (**co-chair**)

2023 The EMBO Young Investigators Sectoral Meeting on Cancer,

 Tel Aviv, Israel (**co-chair**)

2023 Bengaluru – Indian Institute of Sciences (IISc),
Bangalore, India (**invited speaker**)

2023 Chennai – Indian Institute of Technology, Madras (IIT Madras),

 Chennai, India (**invited speaker**)

2023 Trivandrum – Indian Institute of Science Education and Research (IISER TVM),

 Thiruvananthapuram (Trivandrum), India (**invited speaker**)

2023 EMBO eTalk Webinar Series (**chair**, online lecture)

2022 Center For Cancer Research, National Cancer Institute,
Bethesda, USA (**invited speaker**, online lecture)

2022 Computational and Genomic Cancer Research Meeting,
Haifa, Israel (**invited speaker**)

2022 Broad Institute of Harvard and MIT Cancer Program Seminar Series,

 Cambridge, USA (**invited speaker**)

2022 Geisel School of Medicine at Dartmouth University Seminar Series,
Hanover, USA (**invited speaker**)

2022 Duke University ‘Regulatory Networks in Health and Disease’ Seminar Series, Durham, USA (**invited speaker**)

2022 The FASEB Meeting on Consequences of Aneuploidy,
Boston, USA (**invited speaker**)

2022 Olivia Newton-John Cancer Research Institute (ONJCRI) 2022 Seminar Series,
Melbourne, Australia (**invited speaker**; online lecture)

2022 The EMBO Young Investigators Sectoral Meeting on Cancer,

 Benasque, Spain (**invited speaker**)

2022 Medicine 2042 Congress, Tel Aviv, Israel (**invited speaker**)

2022 The EMBO Young Investigators Annual Meeting,
Heidelberg, Germany (**invited speaker**)

2022 The 18th International p53 Workshop, Rehovot, Israel

2022 EMBO Meeting on Chromosome Segregation and Aneuploidy,
Vienna, Austria (**invited speaker**)

2022 Forbeck Meeting on Aneuploidy in Cancer Development, Prognosis and Treatment, Oleggio Castello, Italy (**conference co-chair and invited speaker**)

2022 The Annual Portuguese Genetics Meeting (“Portugaliae Genetica”),
Porto, Portugal (**invited keynote speaker**)

2021 The University of Minnesota Ovarian Cancer Conference,
Minneapolis, USA (**invited keynote speaker**)

2021 The University of Virginia (UVA) Cancer Center Seminar,
Charlottesville, USA (**invited speaker**, online lecture)

2021 The Japanese Cancer Association 80th Annual Meeting,
Yokohama, Japan (**invited speaker**, online lecture)

2021 Harvard Medical School, Boston, USA (**invited speaker**, online lecture)

2021 Front Line Genomics Webinar on Cancer Genomics,
(**invited speaker**, online meeting)

2021 Aneuploidy and Chromosomal Instability Forum,
NY, USA (**invited speaker**, online meeting)

2021 HUGO Human Genome Meeting (**invited speaker**, online meeting)

2021 Regina Elena National Cancer Institute, Rome, Italy (**invited speaker**, online lecture)

2021 The 33rd Annual Lorne Cancer Conference, Lorne, Australia

 (**invited keynote speaker**, online meeting)

2021 ICRF Brilliant Minds Webinar Series (**invited speaker**, online lecture)

2020 The University of Milan, Course on Biomedical Omics for M.Sc. students,
Milan, Italy (**invited speaker**; online lecture)

2020 The UCL Genetics Institute Seminar Series, London, UK

 (**invited speaker**; online lecture)

2020 The Adamas University, Calcutta, India (**invited speaker**; online lecture)

2020 The American Association for Cancer Research (AACR) annual meeting,

 San Diego, USA (**invited speaker**; online meeting)

2020 The European Association for Cancer Research (EACR) 26th congress, Torino, Italy (online meeting)

2020 The European Institute of Oncology (EIO), Milan, Italy (**invited speaker**; cancelled due to COVID-19)

2020 The Annual Portuguese Genetics Meeting (“Portugaliae Genetica”), Porto, Portugal (**invited keynote speaker;** cancelled due to COVID-19)

2019 The Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel (VUB), Brussels, Belgium (**invited speaker**)

2019 The Forbeck Foundation Annual Scholar Retreat, Wisconsin, USA **(invited speaker)**

2019 MIT Center for Precision Cancer Medicine Seminar Series, Cambridge, USA (**invited speaker**)

2019 Gordon Research Conference on Cell Growth and Proliferation, Vermont, USA

2019 EMBO Policy Workshop on Cell Line Heterogeneity, Heidelberg, Germany (**invited speaker**)

2019 EMBO Chromosome Segregation and Aneuploidy Workshop, Cascais, Portugal

2019 The Functional Genomics Consortium, Cambridge, USA (**invited speaker**)

2018 The Forbeck Foundation Annual Scholar Retreat, Wisconsin, USA **(invited speaker)**

2018 EACR-AACR-ISCR Conference: The Cutting Edge of Contemporary Cancer Research, Jerusalem, Israel

2018 The EurOPDX Workshop on Preclinical Models in Clinical Oncology and Cancer Precision Medicine, Weggis, Switzerland (**invited keynote speaker**)

2018 Cold Spring Harbor Laboratory Meeting on Mechanisms and Models of Cancer,
Cold Spring Harbor, USA

2018 The Joint Center for Cancer Genome Discovery (CCGD)-Profile Conference,
Boston, USA (**invited speaker**)

2018 The Human Cancer Models Initiative Meeting, Rockville, USA (**invited speaker**)

2017 The American Society of Cell Biology (ASCB) – European Molecular Biology Organization (EMBO) Annual Meeting, Philadelphia, USA

2017 The Forbeck Foundation Annual Scholar Retreat, Wisconsin, USA **(invited speaker)**

2017 The PSCP-ISCI Genetics Workshop, Sheffield, UK **(invited speaker)**

2016 The Forbeck Foundation Annual Forum, North Carolina, USA

2016 EMBO Fellows meeting, Boston, USA

2016 The International Stem Cell Initiative (ISCI) workshop,
Bar Harbor, USA **(invited session co-chair)**

2016 IPITA-JDRF Key Opinion Leaders Meeting on Stem Cell Derived Beta Cells

 Boston, USA **(invited speaker)**

2016 EMBO Fellows meeting, Heidelberg, Germany

2016 The American Association for Cancer Research (AACR) annual meeting,

 New-Orleans, USA

2015 The American Society for Cell Biology (ASCB) annual meeting,

 San-Diego, USA **(invited speaker)**

2015 The 65th Lindau Nobel Laureate Meeting, Lindau, Germany

2014 Memorial Sloan Kettering Cancer Center, New-York, USA **(invited speaker)**

2014 New Questions, New Answers: NZ Bioethics Conference, Dunedin, New-Zealand

2013 International Society for Stem Cell Research (ISSCR) 11th annual meeting,

 Boston, USA

2012 Drug Safety of Stem Cells and other Novel Therapeutics course,
Liverpool, United Kingdom **(invited speaker)**

2012 International Society for Stem Cell Research (ISSCR) 10th annual meeting,

 Yokohama, Japan

2011 International Society for Stem Cell Research (ISSCR) 9th annual meeting,

 Toronto, Canada

National

2023 ILANIT/FISEB congress of the Federation of the Israeli Societies for Experimental Biology, Eilat, Israel (**invited speaker**)

2023 Department of Microbiology, Immunology and Genetics, Ben-Gurion University,
Beer-Sheva, Israel (**invited speaker**)

2022 Faculty of Life Sciences Seminar Series, Bar Ilan University, Israel
(**invited speaker**)

2022 Faculty of Biology Lecture Series, Technion, Israel

 (**invited speaker**)

2022 Felsenstein Medical Research Center Seminar Series, Petah Tikva, Israel
(**invited speaker**)

2021 Weizmann Institute Cancer Club Lecture Series, Rehovot, Israel

 (**invited speaker**)

2021 Sourasky Medical Center Basic Science Seminar Series, Tel Aviv, Israel
(**invited speaker**)

2021 Israel Society for Cancer Research (ISCR) Annual Meeting
(**invited speaker**, online meeting)

2021 Department of Clinical Biochemistry & Pharmacology, Ben-Gurion University, Beer-Sheva, Israel (**invited speaker**)

2020 From Basic Research to Innovative Therapies, Weizmann Institute, Rehovot, Israel (cancelled due to COVID-19)

2020 ILANIT/FISEB congress of the Federation of the Israeli Societies for Experimental Biology, Eilat, Israel (**invited speaker**)

2020 World Cancer Day, Tel Aviv, Israel (**invited speaker**)

2019 The Annual Meeting of the Israeli Society of Gene and Cell Therapy, Tel Aviv, Israel

2013 Israeli Society of Gene and Cell Therapy (ISGCT) 8th annual meeting,

 Jerusalem, Israel (accepted)

2013 Sheba Cancer Research Center seminar, Ramat-Gan, Israel **(invited speaker)**

2012 The 1st Graduate Students’ Conference in Genetics, Genomics and Evolution,

 Beer-Sheva, Israel (accepted)

2012 Israeli Society for Cancer Research (ISCR) 4th annual meeting,
Ramat-Gan, Israel

2011 Israel Stem Cell Society (ISCS) 4th international meeting,

 Tel Aviv, Israel

2011 ILANIT/FISEB congress of the Federation of the Israeli Societies for Experimental Biology, Eilat, Israel

2010 Israel Stem Cell Society (ISCS) Young Investigators conference,

 Tel Aviv, Israel

Institutional

2023 The TAU Cancer Biology Research Center (CBRC) biennial meeting,
Galilee, Israel (**invited speaker**)

2023 Non-Mendelian Inheritance and Stress Responses Symposium

 Tel Aviv, Israel (**invited speaker**)

2022 Cancer Biology Research Center (CBRC) seminar
(**invited speaker**, online meeting)

2020 1st conference for collaborative research between Safra Center for Bioinformatics and TAU-affiliated hospital-based MDs, Tel Aviv, Israel
(**invited speaker**, online meeting)

2020 The Annual Retreat of the TAU Safra Center for Bioinformatics, Maagan, Israel (**invited speaker**; online meeting)

2018 The 14th Annual Broad Institute Retreat, Boston, USA (**invited speaker**)

2018 The Broad Institute Board of Scientific Counselors Annual Meeting,
Boston, USA (**invited speaker**)

2018 The Broad Institute Trainee Retreat, Boston, USA

2012 Alexander Silberman Institute for the Life Sciences (AS-ILS) annual meeting,

 Ma’agan, Israel

**POSTER PRESENTATIONS**

2018 Dana-Farber/Harvard Cancer Center Cancer Genetics Symposium, Boston, USA

2018 The American Association for Cancer Research (AACR) annual meeting,

 Chicago, USA

2017 The 13th annual Broad Retreat, Boston, USA

2017 The 5th annual Broad-ISF Cell Circuits Symposium, Jerusalem, Israel

2017 The HFSP Fellows Meeting, Lisbon, Portugal

2017 The Klarman Cell Observatory Retreat, Boston, USA

2016 The 12th annual Broad Retreat, Boston, USA

2016 The 4th annual Broad-ISF Cell Circuits Symposium, Boston, USA

2015 Howard Hughes Medical Institute (HHMI) Science Meeting, Janelia, USA

2014 Israeli Society for Cancer Research (ISCR) 6th annual meeting, Haifa, Israel

2013 First Israel-China workshop on Genetics and Epigenetics of Human Disease, Jerusalem, Israel

2013 Israel Stem Cell Society (ISCS) 5th international meeting, Jerusalem, Israel

2013 Stem Cells and Regenerative Medicine conference, Jerusalem, Israel

2013 International Society for Stem Cell Research (ISSCR) 11th annual meeting, Boston, USA

2013 Israeli Society for Cancer Research (ISCR) 5th annual meeting, Beer-Sheva, Israel

2013 Gordon Research Conference on Stem Cells and Cancer,

 Les Diablerets, Switzerland

2012 Faculty of Natural Sciences Posters Contest, Jerusalem, Israel

2011 Israel Society for Cancer Research (ISCR) 3rd annual meeting, Jerusalem, Israel

2011 Molecular Medicine: Cancer Biology and Therapy conference, Jerusalem, Israel

2011 UK-Israel Regenerative Medicine Conference, Beer-Sheva, Israel

**TRAINEES’ AWARDS & ORAL PRESENTATIONS**

Yael Cohen-Sharir: 2022 Research Excellence Award, Faculty of Medicine, TAU

Hajime Okada: TAU Excellence Postdoctoral Fellowship; Japanese Society for the Promotion of Science Postdoctoral Fellowship; Uehara Postdoctoral Fellowship

Michal Getz: MD thesis (Avodat Gmar): Grade 100; selected oral presentation at the annual competition of excellent MD theses (3rd place winner); selected oral presentation at the CBRC Virtual Seminar; Outstanding research project award by the Cancer Biology Research Center (CBRC)

Johanna Zerbib: CBRC & Constantiner travel awards; selected oral presentation at the Israeli Society for Cancer Research (ISCR) annual meeting (May 2022); selected flash talks at ILANIT 2023 and CBRC biennial meeting 2023; Pfizer-Wexler PhD Scholarship; best flash talk award at the CBRC biennial meeting 2023

Kavya Prasad: Best poster award (2nd place) at the Safra Bioinformatics Annual Retreat 2020; selected oral presentation at the CBRC Virtual Seminar

Tom Winkler: Djerassi Institute of Oncology travel grant; selected flash talk at ILANIT 2023

Gil Leor: Cancer Biology Research Center travel award

Linoy Raz: Selected flash talk at ILANIT 2023; Best flash talk award at ILANIT 2023

**PUBLICATIONS**

Total number of citations: 6,889; H-index: 29; i10-index: 40; (Google Scholar, January 1st, 2023)

#Corresponding author; \*Equally-contributing first-author; Ben-David lab members

**ORIGINAL RESEARCH ARTICLES**

**2023**

1. ChangT., CaoY., ShulmanE.D., **Ben-DavidU.**, Schäffer A.A., and Ruppin E. Optimizing cancer immunotherapy response prediction by tumor aneuploidy score and fraction of copy number alterations. ***Npj Precision Oncology*** (accepted) **IF=10.1**
2. Stossel C., Raitses-Gurevich M., Atias D., Beller T., Gorman-Glick Y., Halperin S., Peer E., Denroche R.E., Zhang A., Notta F., Wilson J.M., O’Kane G., Haimov Talmoud E., Amison N., Schvimer M., Salpether S., Bar V., Tirosh I., Tal R., Dinstag G., Eliezer Y., **Ben-David U.**, Straussman R., Gavert N., Gallinger S., Berger R., Golan T. Spectrum of response to platinum and PARP inhibitors in germline BRCA-associated pancreatic cancer in the clinical and preclinical setting. ***Cancer Discovery*** (accepted). **IF=39.4**.
3. Altea-ManzanoP., Doglioni G., Liu Y., Cuadros A.M., Nolan E., Fernandez-Garcia J., Wu Q., Montagne A., Planque M., Laue K.J., Cidre-Aranaz F., Liu X., Marin-Bejar O., Van Elsen J., Vermeire I., Broekaert D., Demeyer S., Spotbeen X., Alkan H.F., Demicco M., Rabas N., Riera-Domingo C., Richard F., Geukens T., Maxim De Schepper14, Sophia Leduc5, Sigrid Hatse5, Yentl Lambrechts5, Emily Jane Kay15, Sergio Lilla15, Alekseenko A., Geldhof V., Boeckx B.,, de la Calle Arregui C., Floris G., Swinnen J., Marine J.C., Lambrechts D., Pelechano V.,Mazzone M., Zanivan S., Cools J., Wildiers H., Baud V., Grünewald T.G.P., **Ben-David U.**, Desmedt C., Malanchi I., Fendt S.-M. A palmitate-rich metastatic niche enables metastasis growth via p65 acetylation resulting in preo-metastatic NF-κB signaling. ***Nature Cancer***, 2023, doi: 10.1038/s43018-023-00513-2 (online ahead of print). **IF=23.2.**
4. Garriba L.\*, De Feudis G.\*, Martis V., Galli M., Dumont M., Eliezer Y., Wardenaar R., Ippolito M., Iyer D.R., Tijhuis A.E., Spierings D.C.J., Schubert M., Rind N., Foijer F., **Ben-David U.**, Fachinetti D., Doksani Y., and Santaguida S. Short-term molecular consequences of chromosome mis-segregation for genome stability. ***Nature Communications***, 2023, 14(1):1353, doi: 10.1038/s41467-023-37095-7. **IF=17.7**.

**2022**

1. Waissengrin B., ZahaviT., Salmon‐DivonM., GoldbergA., Wolf I., Rubinek T. Winkler T., Farkash O., GrinshpunA., Zubkov A., Khatib M., Strulov Shachar S., Keren N., Carmi-Levy I., **Ben-DavidU.**, and Amir Sonnenblick1,2\*. The effect of non-oncology drugs on clinical and genomic risk in early luminal breast cancer. ***ESMO Open***, 2022, 7(6):100648, doi: 10.1016/j.esmoop.2022.100648. **IF=5.3**.
2. Nahmad A.D.\*, Reuveni E.\*, Goldschmidt E.\*, Tenne T., Liberman M., Horovitz-Fried M., Khosravi R., Kobo H., Reinstein E., Madi. A. #, **Ben-David U.** #, and Barzel A. # Frequent aneuploidy in primary human T cells following CRISPR-Cas9 cleavage. ***Nat Biotechnol***, 2022, 40(12):1807-1813, doi: 10.1038/s41587-022-01377-0. **IF=54.9**.

# Highlighted in news stories in the popular press (Haaretz, Jerusalem Post, ScienceDaily, and more)

1. Hoge A.C.H.\*, Getz M.\*, Beroukhim R., Golub T.R., Ha G.# and **Ben-David U.**# DNA-based copy number analysis confirms genomic evolution of PDX models. ***npj Precision Oncology***, 2022, 6(1):30. **IF=10.1**
2. Prasad K., BloomfieldM., LeviH., KeuperK., BernhardS.V., BaudoinN.C., LeorG., Eliezer Y., GiamM., WongC.K., RancatiG., StorchovaZ., Cimini D.,and **Ben-David U.** # Whole-genome duplication shapes the aneuploidy landscape of human cancers. ***Cancer Research***, 2022, 3;82(9):1736-1752., doi:10.1158/0008-5472.CAN-21-2065. **IF=12.7**

**2021**

1. Ippolito M., Martis V., Hong C., Wardenaar R., Zerbib J., Spierings D.C.J., **Ben-David U.**, Foijer F., and Santaguida S. Gene copy-number changes and chromosomal instability induced by aneuploidy confer resistance to chemotherapy. ***Developmental Cell***, 2021, S1534-5807(21)00562-1,doi: 10.1016/j.devcel.2021.07.006.**IF=10.1**

# Mentioned on the Cover of the journal

1. Vaz S., Ferreira F.J., Macedo J.C., Leor G., **Ben-David U.**, Bessa J., and Logarinho E. BMF repression by FoxM1 inhibits anoikis during mitosis and is a biomarker for antimitotic chemotherapy response. ***Cell Death & Disease****,* 2021, 12(6):542, doi: 10.1038/s41419-021-03822-5. **IF=8.5**.
2. Wang R.W., Vigano S., **Ben-David U.**, Amon A., and Santaguida S. Aneuploid senescent cells activate NF-κB to promote their immune clearance by NK cells. ***EMBO Reports*** 2021, 22(8):e52032,doi: 10.15252/embr.202052032. **IF=8.8**.
3. Cohen-SharirY., McFarlandJ., AbdusamadM., MarquisC., BernhardS.V., KazachkovaM., TangH., IppolitoM.R., LaueK., Zerbib J., MalabyH.L.H., JonesH., Stautmeister L.-M., Bockaj I., Wardenaar R., LyonsN., NagarajaA., BassA.J., Spierings D.C.J., Foijer F., BeroukhimR., SantaguidaS., Golub T.R., StumpffJ., Storchova Z.,and **Ben-David U.#** Aneuploidy renders cancer cells vulnerable to mitotic checkpoint inhibition. ***Nature*** 2021, 590(7846):486-491, doi: 10.1038/s41586-020-03114-6. **IF=50.0**

# "Research Highlight” in ***Cancer Discovery*** (doi: 0.1158/2159-8290.CD-RW2021-017)

# “News & Views” comment in ***Nature Communications*** (doi: 10.1038/s41467-021-23965-5)

# A provisional patent application was submitted based on this work.

# Highlighted in news stories in the popular press (**New York Post**, **Ynet**, **GEN**, **Doctors Only**, and more)

# “Best Publication Award” of the Faculty of Medicine at TAU for the year 2021
# Inspired clinical trials conducted in the U.S.A. by Amgen and Volastra

**2020**

1. Replogle J., Zhou W., Amaro A., McFarland J., Villalobos-Oritz M., Ryan J., Letai, A., Yilmaz O., Sheltzer J., Lippard S., **Ben-David U.**, and Amon A. Aneuploidy increases resistance to chemotherapeutics by antagonizing cell division. ***Proc Natl Acad Sci U S A***, 2020, 117(48):30566-30576, doi.org/10.1073/pnas.2009506117. **IF=11.2**.
2. Winkler T. and **Ben-David U. #** Elevated ACE2 expression levels in tumor-adjacent tissues of cancer patients. ***International Journal of Cancer***, 2020, 147(11):3264-3266, doi.org/10.1002/ijc.33145. ***IF=7.4***

# Selected for a special issue for the 2021 World Cancer Day

1. Enache O.M.\*, Rendo V.\*, AbdusamadM., LamD., DavisonD., PalS., CurrimjeeN., Hess J., SansonK., PantelS., NagA., ThornerA., RootD., DoenchJ.G., VazquezF., BeroukhimR., GolubT.R., and **Ben-David U.#** Cas9 activates the p53 pathway and selects for p53-inactivating mutations. ***Nature Genetics***, 2020, 52(7):662-668, doi: 10.1038/s41588-020-0623-4. **IF=38.3**

# The cover of the journal was dedicated to this article

# “Research Highlight” in **Cancer Discovery** (doi: 10.1158/2159-8290.CD-RW2020-081)

# Invited paper presentation in **JRNLclub** (<https://jrnlclub.org/>)

# A provisional patent application was submitted based on this work

1. Corsello S.M., Nagari R.T., Spangler R.D., Rossen J., Kocak M., Bryan J.G., Humeidi R., Peck D., Wu X., Tang A.A., Wang V.M., Bender S.A., Lemire E., Narayan R., Montgomery P., **Ben-David U.**, Chen Y., Rees M.G., Lyons N.J., McFarland J.M., Wong B.T., Wang L., Dumont N., O'Hearn P.J., Stefan E., Doench J.G., Greulich H., Meyerson M., Vazquez F., Subramanian A., Roth J.A., Bittker J.A., Boehm J.S., Mader C.C., Tsherniak A., and Golub T.R. Discovering the anticancer potential of non-oncology drugs by systematic viability profiling. ***Nature Cancer***, 2020, 1(2):235-248, doi: 10.1038/s43018-019-0018-6. **IF=23.2**

**2018**

1. **Ben-DavidU.**,SiranosianB., Ha G., TangH., OrenY., HinoharaK., Strathdeec.A., DempsterJ., LyonsN.J., BurnsR., NagA., KugenerG., CiminiB., TsvetkovP., MaruvkaY.E., O’RourkeR., GarrityA., TubelliA.A., BandopadhayayP., TsherniakA., VazquezF., WongB., BirgerC., GhandiM, ThornerA.R., BittkerJ.A., MeyersonM., GetzG., Beroukhim R. and Golub T.R. Genetic and transcriptional evolution alters cancer cell line drug response. ***Nature***, 2018, 560(7718):325-330, doi: 10.1038/s41586-018-0409-3. **IF=50.0**

# The cover of the journal was dedicated to this article

# Highlighted in a Broad Press Release and Video

# Highlighted in a “News and Views” article in ***Disease Models & Mechanisms***
(doi: 10.1242/dmm.037366)

# Highlighted in news stories in the popular press (**STAT+**, **Haaretz**, and more)

1. Abdeen S.A., **Ben-David U.**, Maly B. and Aqueilan R. Somatic loss of WWOX drives triple-negative breast cancer through perturbation of TP53. ***Cell Death & Disease***, 2018, 9(8):832, doi: 10.1038/s41419-018-0896-z. **IF =8.5**

**2017**

1. **Ben-DavidU.**, Ha G., TsengY.Y., Greenwald N.F., OhC., Shih J., McFarland J.M., WongB., Boehm J.S., BeroukhimR. and Golub T.R. Patient-derived xenografts undergo mouse-specific tumor evolution. ***Nature Genetics***, 2017, 49(11):1567-1575, doi:10.1038/ng.3967. **IF= 38.3**

# Highlighted in a “News and Views” article in ***Nature Genetics*** (doi:10.1038/ng.3983)

# Highlighted in two news stories in ***Nature***(doi:10.1038/nature.2017.22782 and
doi: 10.1038/d41586-018-05890-8)

# Highlighted in a news story in ***Cancer Discovery*** (doi: 10.1158/2159-8290.CD-NB2017-151)

# Highlighted in news stories in the popular press (***The Scientist***, ***Ars Technica***, and more)

# “The Research Parasite Award” for outstanding secondary data analysis

**2016**

1. Bi W.L., Horowtiz P., Greenwald N., Abedalthagafi M., Agarwalla P.K., Gibson W.J., Mei Y, Schumacher S.E., **Ben-David U.**, Chevalier A., Carter S.L., Tiao G., Brastianos P.K., Ligon A.H., Ducar M., MacConaill L.E., Laws E.R., Santagata S., Beroukhim R., Dunn IF. Landscape of genomic alterations in pituitary adenomas. ***Clinical Cancer Research***, 2016, 23(7):1841-1851, doi: 10.1158/1078-0432.CCR-16-0790. **IF=12.5**
2. Aguirre A., Meyers R., Weir B., Vazquez F., Zhang C.Z., **Ben-David U.**, Cook A., Ha G., Harrington W., Doshi M., Gill S., Xu H., Ali L., Jiang G., Pantel S., Lee Y., Goodale A., Cherniack A., Oh C., Kryukov G., Cowley G., Garraway L., Stegmaier K., Roberts C., Golub T.R., Meyerson M., Root D., Tsherniak A., and Hahn W. Genomic copy number dictates a gene-independent cell response to CRISPR-Cas9 targeting. ***Cancer Discovery***, 2016, 6(8):914-29, doi: 10.1158/2159-8290.CD-16-0154. **IF=39.4**
3. **Ben-David U.**, Ha G., Khadka P., Jin X., Wong B., Franke L. and Golub T.R. The landscape of chromosomal aberrations in breast cancer mouse models reveals driver-specific routes to tumorigenesis. ***Nature Communications***, 2016, 7:12160, doi:10.1038/ncomms12160. **IF=14.9**
4. Lamm N., **Ben-David U.**, Kerem B. and Benvenisty N. Genomic instability in human pluripotent stem cells arises from replicative stress and chromosome condensation defects. ***Cell Stem Cell***, 2016, 18(2): 253-61, doi: 10.1016/j.stem.2015.11.003. **IF=24.6**

**2015**

1. **Ben-David U.**, Cowell Ian G., Austin Caroline C. and Benvenisty N. Controlling the survival of human pluripotent stem cells by small molecule-based targeting of topoisomerase II alpha. ***Stem Cells***, 2015, 33(3): 1013-9, doi: 10.1002/stem.1888. **IF=6.3**

# Highlighted in the journal's website

**2014**

1. Weissbein U., **Ben-David U.** and Benvenisty N. Virtual karyotyping reveals greater chromosomal stability in neural cells derived by transdifferentiation than those from stem cells. ***Cell Stem Cell***, 2014, 15(6):687-91, doi: 10.1016/j.stem.2014.10.018. **IF=24.6**
2. **Ben-David U.**, Arad G., WeissbeinU., MandefroB., MaimonA., NarwaniK., ClarkA.T., AndrewsP.W., BenvenistyN., and Biancotti J.C. Aneuploidy induces profound changes in gene expression, proliferation and tumorigenicity of human pluripotent stem cells. ***Nature Communications***, 2014, 5:4825, doi: 10.1038/ncomms5825. **IF=14.9**
3. **Ben-David U.**\*, Biran A.\*, Scaffidi P., Boehringer M., Meshorer E. and Benvenisty N. Elimination of undifferentiated cancer cells by pluripotent stem cell inhibitors. ***Journal of Molecular Cell Biology***, 2014, 6(3):267-9, doi: 10.1093/jmcb/mju012. **IF=6.2**
4. **Ben-David U.** and Benvenisty N.Chemical ablation of tumor-initiating human pluripotent stem cells. ***Nature Protocols***, 2014, 9(3):729-40, doi: 10.1038/nprot.2014.050. **IF=13.5**

**2013**

1. **Ben-David U.**, Nudel N. and Benvenisty N. Immunologic and chemical targeting of the tight-junction protein Claudin-6 eliminates tumorigenic human pluripotent stem cells. ***Nature Communications*,** 2013, 4:1992, doi:10.1038/ncomms2992. **IF=14.9**

# Highlighted in the journal's website and press release

# Highlighted in "Scientific American", "A Week in Science" and "Lab Times" magazines

# "Article of the month” award, Life Sciences Institute, Hebrew University

1. **Ben-DavidU.**, GanQ.F., Golan-LevT., AroraP., YanukaO., OrenY.S., Leikin-Frenkel A., GrafM., GarippaR., BoehringerM., GromoG. and Benvenisty N. Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen. ***Cell Stem Cell***, 2013, 12(2):167-79, doi: 10.1016/j.stem.2012.11.015. **IF=24.6**

# "Research Highlight" in ***Nature Chemical Biology***, 2013, 9(3): 139

 # "Research Highlight" in ***Nature/SciBX****,* 2013, 6(5): doi:10.1038/scibx.2013.126

 # “Article of the month” award, Life Sciences Institute, Hebrew University

# US granted patent 9,456,998, of May 22, 2013, SELECTIVE INHIBITORS OF UNDIFFERENTIATED CELLS

1. Lee P., Martin N.T., Nakamura K., Azghadi S., Amiri M., **Ben-David U.**, Perlman S., Gatti R.A., Hu H. and Lowry W.E. SMRT compounds abrogate cellular phenotypes of Ataxia Telangiectasia in neural derivatives of patient specific hiPSCs. ***Nature Communications***, 2013, 4:1824, doi:10.1038/ncomms2824. **IF=14.9**
2. **Ben-David U.**, Mayshar Y. and Benvenisty N. Virtual karyotyping of pluripotent stem cells on the basis of their global gene expression profiles. ***Nature Protocols***, 2013, 8(5): 989-97,doi: 10.1038/nprot.2013.051. **IF=13.5**

# Highlighted in the journal's website

**2012**

1. **Ben-David U.** and Benvenisty N. High prevalence of evolutionarily conserved and species-specific genomic aberrations in mouse pluripotent stem cells. ***Stem Cells***, 2012, 30(4):612-22,doi: 10.1002/stem.1057. **IF=6.3**

 # Highlighted on the cover of the journal and in its website

 # “Article of the month” award, Life Sciences Institute, Hebrew University

**2011**

1. **Ben-David U.**, Mayshar Y. and Benvenisty N. Large-scale analysis reveals acquisition of lineage-specific chromosomal aberrations in human adult stem cells. ***Cell Stem Cell***, 2011, 9(2):97-102, doi: 10.1016/j.stem.2011.06.013. **IF=24.6**

 # Highlighted in the Editorial and in a Perspective article published in the same issue

 # “Article of the month” award, Life Sciences Institute, Hebrew University

**2010**

1. Mayshar Y.\*, **Ben-David U.\***, Lavon N., Biancotti J.C., Yakir B., Clark A.T., Plath K., Lowry W.E. and Benvenisty N. Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. ***Cell Stem Cell***, 2010, 7(4):521-31**,** doi: 10.1016/j.stem.2010.07.017. **IF=24.6**

 # "Research Highlight" in ***Nature Reviews Cancer***, 2010, 10(11):742

 # “Research Highlight” in ***Nature Methods***, 2010, 7(12): 948-9

 # “Article of the year” award, 2010, Life Sciences Institute, Hebrew University

**SUBMITTED MANUSCRIPTS**

1. de la Vega A.A., Temiz N.A., Tasakis R., Somogyi K., Reuveni E., **Ben-David U.**, Stenzinger A., Poth, T., Papavasiliou N., Harris R.S., and Sotillo R. Acute Expression of human APOBEC3CB in mice causes lethality associated with RNA editing. ***Submitted***.
<https://doi.org/10.1101/2022.06.01.494353> (bioRxiv)
2. Nagaraja K.N., Wu, Z., Zhou, J., Goss L.B., Jeffries A., Bao C., Liu Y., Ho Z.V., Wang V.M., McFarland J.M., **Ben-David U.**, Augustin J., Liao J., Zhang Y., Zhang C.-Z., Rustgi A.K., Wong K.-K., and Bass, A.J. Cyclin E1 Amplification Promotes Chromosomal Instability and Distinct Vulnerabilities in Gastroesophageal Adenocarcinoma. ***Submitted***.
3. Zerbib J. \*, Ippolito M. R.\*, EliezerY., Reuveni E., Viganò S., De FeudisG., Savir KadmonA., Martin S., LeorG., BerstlerJ., LaueK., Cohen-SharirY., ScorzoniS., VazquezF., **Ben-David U.** #, and Stefano Santaguida #. Human aneuploid cells depend on the RAF/MEK/ERK pathway for overcoming increased DNA damage. ***Submitted.*** <https://doi.org/10.1101/2023.01.27.525822> (bioRxiv)
4. Ippolito M. R.\*, Zerbib J. \*, Reuveni E., De FeudisG., EliezerY., Savir KadmonA., Martin S., Viganò S., LeorG., BerstlerJ., LaueK., Cohen-SharirY., ScorzoniS., VazquezF., Stefano Santaguida#, and **Ben-David U.** #. Increased RNA and protein degradation is required for counteracting transcriptional burden and proteotoxic stress in human aneuploid cells. ***Submitted***. <https://doi.org/10.1101/2023.01.27.525826> (bioRxiv)
5. Sacconi A. \*, Muti P. \*, Pulito C., Pellini R., Strano S., **Ben-David U.**, Bossi P. # and Blandino G. #. Molecular profiling in head and neck squamous cell carcinoma patients targets potential responsiveness to immune checkpoint inhibitors. ***Submitted***.
6. Rabinowitz R. \*, Shor O. \*, Zerbib J. \*, Herman S., Zelikson N., Mediwale S., Yom-Tov N., **Ben-David U.**, Benninger F. # and Offen D #. Computationally engineered CRISPR-SpyCas9 high-fidelity variants with improved specificity and reduced non-specific DNA damage. ***Submitted***. <https://doi.org/10.1101/2023.04.11.536265> (bioRxiv)

**REVIEWS & PERSPECTIVES**

**2023**

1. Prasad K. and **Ben-David U. #** A balance act: how whole-genome doubling and aneuploidy interact in human cancer. ***Oncotarget****,* 2023 (accepted). **IF=3.3**

**2022**

1. Eliezer Y. and **Ben-David U.#** Double genome, double jeopardy. ***Nature***, 2022, doi.org/10.1038/d41586-022-00849-2w. **IF=50.0**

**2021**

1. Cohen-Sharir Y. and **Ben-David U.**# Relevance of aneuploidy for cancer therapies targeting the spindle assembly checkpoint and KIF18A. ***Molecular & Cellular Oncology***, 2021, 8(3):1915075, doi.org/10.1080/23723556.2021.1915075. **IF=1.2**

**2020**

1. Rendo V., Enache O. and **Ben-David U. #** Adding to the CASeload: Unwarranted Cas9-induced activation of the p53 pathway. ***Molecular & Cellular Oncology***, 2020, 7(5):1789419, doi.org/10.1080/23723556.2020.1789419. **IF=1.2**
2. **Ben-David U.#**and Amon A. Context is everything: aneuploidy in cancer. ***Nature Reviews Genetics***, 2020, 21(1):44-62, doi: 10.1038/s441576-019-0171-x. **IF=53.2**

# Highlighted on the cover of the journal

**2019**

1. **Ben-David U. #**, Beroukhim R. and Golub T.R. Genomic evolution of cancer models: perils and opportunities. ***Nature Reviews Cancer***, 2019, 19(2):97-109, doi: 10.1038/s41568-018-0095-3. **IF=60.7.**

**2018**

1. Odorico. J., Adams A., Melton D., Greenstein G., Hwa A., Nostro C., Rezania A., Oberholzer J., Pipeleers D., Yang L., Cowan C., Huangfu D., Egli D., **Ben-David U.**, Vallier L., Grey S., Tang Q., Roep B., Ricordi C., Naji A., Orlando G., Anderson D., Poznansky M., Ludwig B., Tomei A., Greiner D., Graham M., Carpenter M., Migliaccio G., D’Amour K., Hering B., Piemonti L., Berney T., Rickels M., Kay T. and Markmann J. Report of the Key Opinion Leaders Meeting on Stem Cell-Derived Beta Cells. ***Transplantation***, 2018, 102(8):1223-1229, doi: 10.1097/TP.0000000000002217. **IF=4.9**

**2017**

1. Andrews P.W., **Ben-David U.**, Benvenisty N., Coffey P., Eggan K., Knowles B.B., Nagy A., Pera M., Reubinoff B., Rugg-Gunn P.J., Stacey G.N. Assessing the safety of human pluripotent stem cells (PSCs) and their derivatives for clinical applications. ***Stem Cell Reports***, 2017, 9(1):1-4, doi: 10.1016/j.stemcr.2017.05.029. **IF=7.8**

**2015**

1. Heslop A.J., Hammond T.G., Santeramo I., Piella A.T., Hopp I., Zhou J., Baty R., Graziano, E.I., Bernabe P., Shaw D.A., Bunn I., Caron A., Skold P., Andrews P.W., Baxter M., Hay D., Hamdam J., Sethu S., Sharpe M.E., Patel S., Jones D.R., Reinhardt J., Danen E.H.J., **Ben-David U.**, Stacey G., Bjorquist P., Rowe, C., Pellegrini G., Antoine D., Cross M.J., Murray P., Williams D., Kitteringham N.R., Park B.K. and Goldring C.E.P. Understanding the risks of stem cell-based therapeutics. ***Stem Cells Translational Medicine***, 2015, 4(4):389-400, doi: 10.5966/sctm.2014-0110. **IF=6.9**

**2014**

1. **Ben-David U.**# Genomic instability, driver genes and cell selection: Projections from cancer to stem cells. ***Biochim Biophys Acta***, 2014, 1849(4):427-35, doi: 10.1016/j.bbagrm.2014.08.005. **IF=4.5**

# Highlighted on the cover of the journal

1. Weissbein U., Benvenisty N. and **Ben-David U.#** Genome maintenance in pluripotent stem cells. ***Journal of Cell Biology*** 2014, 204(2):153-63,doi: 10.1083/jcb.201310135. **IF=10.5**

**2013**

1. **Ben-David U.#** Flowing through the CRISPR-CAScade: Will genome editing boost cell therapies? ***Molecular and Cellular Therapies***, 2013, 1:3, doi:10.1186/2052-8426-1-3. No IF available.

1. **Ben-David U.**, Nissenbaum J. and Benvenisty N. New balance in pluripotency: reprogramming with lineage specifiers. ***Cell*,** 2013, 153(5): 939-40, doi: 10.1016/j.cell.2013.04.051. **IF=41.6**

**2012**

1. **Ben-David U.**, Kopper O. and Benvenisty N. Expanding the boundaries of embryonic stem cells. ***Cell Stem Cell***, 2012, 10(6):666-77,doi: 10.1016/j.stem.2012.05.003. **IF=24.6**
2. **Ben-David U.** and Benvenisty N. Analyzing the genomic integrity of stem cells. ***StemBook***,2012, doi: 10.3824/stembook.1.50.1, http://www.stembook.org.No IF available.
3. **Ben-David U.**, Mayshar Y. and Benvenisty N. Significant acquisition of chromosomal aberrations in human adult mesenchymal stem cells: Response to Sensenbé et al. ***Cell Stem Cell***, 2012, 10(1):10-11, doi: 10.1016/j.stem.2011.12.007. **IF=24.6**

**2011**

1. Goldring C.E.P., Duffy P.A., Benvenisty N., Andrews P.W., **Ben-David U.**, Eakins R., French N., Hanley N.A., Kelly L., Kitteringham N.R., Kurth J., Ladenheim D., Laverty H., McBlane J., Narayanan G., Patel S., Reinhardt J, Rossi A., Sharpe M. and Park K. Assessing the safety of stem cell therapeutics. ***Cell Stem Cell***, 2011, 8(6):618-28, doi: 10.1016/j.stem.2011.05.012. **IF=24.6**

# The cover and the editorial of the journal were dedicated to this article

1. **Ben-David U.** and Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent stem cells. ***Nature Reviews Cancer***, 2011, 11(4): 268-77, doi: 10.1038/nrc3034. **IF=60.7**

 # The cover and the editorial of the journal were dedicated to this article

**2010**

1. **Ben-David U.**, Benvenisty N. and Mayshar Y. Genetic instability in human induced pluripotent stem cells: Classification of causes and possible safeguards. ***Cell Cycle***, 2010, 9(23): 4603-4, doi: 10.4161/cc.9.23.14094. **IF=4.5**